Role of Adenosine Kinase Inhibitor in Adenosine Augmentation Therapy for Epilepsy: A Potential Novel Drug for Epilepsy

Xiongfei       Wang; Tianfu       Li

doi:10.2174/1389450119666191014104347

Abstract

Epilepsy, an ancient disease, is defined as an enduring predisposition to generate epileptic seizures and by the neurobiological, cognitive, psychological, and social consequences of this condition. Antiepileptic drugs (AEDs) are currently used as first-line treatment for patients with epilepsy; however, around 36% of patients are diagnosed with refractory epilepsy, which means two or more AEDs have been considered as failed after sufficiently correct usage. Unfortunately, it is unlikely that the improvement of the efficacy of AEDs will be easily achieved, especially since no AEDs show efficacy in ceasing epileptogenesis. Consequently, several endogenous anticonvulsants attract investigators and epileptologists, such as galanin, cannabis, and adenosine.

Astrogliosis is a neuropathological hallmark of epilepsy, whatever the etiology is, and astrogliosis is frequently associated with overexpression of adenosine kinase, which means downregulation of synaptic levels of adenosine. Consequently, adenosine is negatively regulated by adenosine kinase through the astrocyte-based cycle. On the other hand, focal adenosine augmentation therapy, using adenosine kinase inhibitor, has been proved to be effective for reducing seizures in both animal models and in vitro human brain tissue resected from a variety of etiology of refractory epilepsy patients. In addition to reducing seizures, adenosine augmentation therapy can also palliate co-morbidities, like sleep, cognition, or depression. Of importance, transgenic mice with reduced ADK were resistant to epileptogenesis induced by acute brain injury. In terms of translation, based on findings of adenosinerelated epileptogenic mechanisms, the application into clinical practice seems to be feasible by molecular strategies that have been already experimentally implemented, including gene and RNA interference.

In the present review, we will focus on the evidence of ADK dysfunction in the epileptic brain from human beings and animals, and review the role of ADK inhibitor in adenosine augmentation therapy and the underlying mechanism of prevention of epileptogenesis.

Keywords: Epilepsy, epileptogenesis, adenosine, adenosine kinase, adenosine kinase inhibitor, cannabis.

« Previous Next »

[1] 
Temkin O. The falling sickness: A history of epilepsy from the Greeks to the beginnings of modern neurology. JHU Press 1994.
[2] 
Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol  2018; 75(3): 279-86.
[http://dx.doi.org/10.1001/jamaneurol.2017.3949] [PMID:  29279892] 
[3] 
Hauser WA. An unparalleled assessment of the global burden of epilepsy. Lancet Neurol  2019; 18(4): 322-4.
[http://dx.doi.org/10.1016/S1474-4422(19)30042-0] [PMID:  30773429] 
[4] 
Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med  2011; 365(10): 919-26.
[http://dx.doi.org/10.1056/NEJMra1004418] [PMID:  21899452] 
[5] 
Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia  2005; 46(6): 858-77.
[http://dx.doi.org/10.1111/j.1528-1167.2005.54904.x] [PMID:  15946327] 
[6] 
Boison D. Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmacol Sci  2006; 27(12): 652-8.
[http://dx.doi.org/10.1016/j.tips.2006.10.008] [PMID:  17056128] 
[7] 
Newby AC, Worku Y, Holmquist CA. Adenosine formation. Evidence for a direct biochemical link with energy metabolism. Adv Myocardiol  1985; 6: 273-84.
[PMID:  2986260] 
[8] 
Boison D, Chen JF, Fredholm BB. Adenosine signaling and function in glial cells. Cell Death Differ  2010; 17(7): 1071-82.
[http://dx.doi.org/10.1038/cdd.2009.131] [PMID:  19763139] 
[9] 
Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM. Adenosine and brain function. Int Rev Neurobiol  2005; 63: 191-270.
[http://dx.doi.org/10.1016/S0074-7742(05)63007-3] [PMID:  15797469] 
[10] 
Fedele DE, Li T, Lan JQ, Fredholm BB, Boison D. Adenosine A1 receptors are crucial in keeping an epileptic focus localized. Exp Neurol  2006; 200(1): 184-90.
[http://dx.doi.org/10.1016/j.expneurol.2006.02.133] [PMID:  16750195] 
[11] 
Chen F, He X, Luan G, Li T. Role of DNA Methylation and Adenosine in Ketogenic Diet for Pharmacoresistant Epilepsy: Focus on Epileptogenesis and Associated Comorbidities. Front Neurol  2019; 10: 119.
[http://dx.doi.org/10.3389/fneur.2019.00119] [PMID:  30863356] 
[12] 
Sebastião AM, Ribeiro JA. Tuning and fine-tuning of synapses with adenosine. Curr Neuropharmacol  2009; 7(3): 180-94.
[http://dx.doi.org/10.2174/157015909789152128] [PMID:  20190960] 
[13] 
Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol  2009; 51(3): 528-34.
[http://dx.doi.org/10.1016/j.jhep.2009.04.021] [PMID:  19596476] 
[14] 
Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA. Glia and epilepsy: excitability and inflammation. Trends Neurosci  2013; 36(3): 174-84.
[http://dx.doi.org/10.1016/j.tins.2012.11.008] [PMID:  23298414] 
[15] 
Fedele DE, Gouder N, Güttinger M, et al. Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation. Brain  2005; 128(Pt 10): 2383-95.
[http://dx.doi.org/10.1093/brain/awh555] [PMID:  15930047] 
[16] 
Wang X, He X, Luan G. Comorbidities of refractory epilepsy and
  the update mechanism. neuropsychiatry (London)  2017; 1(S1): 45-8.
[http://dx.doi.org/10.4172/Neuropsychiatry.1000S1007] 
[17] 
Knake S, Hamer HM, Rosenow F. Status epilepticus: a critical review. Epilepsy Behav  2009; 15(1): 10-4.
[http://dx.doi.org/10.1016/j.yebeh.2009.02.027] [PMID:  19236943] 
[18] 
Gouder N, Scheurer L, Fritschy JM, Boison D. Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. J Neurosci  2004; 24(3): 692-701.
[http://dx.doi.org/10.1523/JNEUROSCI.4781-03.2004] [PMID:  14736855] 
[19] 
Li T, Lytle N, Lan JQ, Sandau US, Boison D. Local disruption of glial adenosine homeostasis in mice associates with focal electrographic seizures: a first step in epileptogenesis? Glia  2012; 60(1): 83-95.
[http://dx.doi.org/10.1002/glia.21250] [PMID:  21964979] 
[20] 
Lenkov DN, Volnova AB, Pope AR, Tsytsarev V. Advantages and limitations of brain imaging methods in the research of absence epilepsy in humans and animal models. J Neurosci Methods  2013; 212(2): 195-202.
[http://dx.doi.org/10.1016/j.jneumeth.2012.10.018] [PMID:  23137652] 
[21] 
Wang X, He X, Li T, Shu Y, Qi S, Luan G. Anti-epileptic effect of ifenprodil on neocortical pyramidal neurons in patients with malformations of cortical development. Exp Ther Med  2017; 14(6): 5757-66.
[http://dx.doi.org/10.3892/etm.2017.5311] [PMID:  29285118] 
[22] 
Sofroniew MV. Astrogliosis. Cold Spring Harb Perspect Biol  2014; 7(2)a020420
[http://dx.doi.org/10.1101/cshperspect.a020420] [PMID:  25380660] 
[23] 
Aronica E, Sandau US, Iyer A, Boison D. Glial adenosine kinase--a neuropathological marker of the epileptic brain. Neurochem Int  2013; 63(7): 688-95.
[http://dx.doi.org/10.1016/j.neuint.2013.01.028] [PMID:  23385089] 
[24] 
Aronica E, Zurolo E, Iyer A, et al. Upregulation of adenosine kinase in astrocytes in experimental and human temporal lobe epilepsy. Epilepsia  2011; 52(9): 1645-55.
[http://dx.doi.org/10.1111/j.1528-1167.2011.03115.x] [PMID:  21635241] 
[25] 
Adams KL, Gallo V. The diversity and disparity of the glial scar. Nat Neurosci  2018; 21(1): 9-15.
[http://dx.doi.org/10.1038/s41593-017-0033-9] [PMID:  29269757] 
[26] 
Eid T, Williamson A, Lee TS, Petroff OA, de Lanerolle NC. Glutamate and astrocytes--key players in human mesial temporal lobe epilepsy? Epilepsia  2008; 49(Suppl. 2): 42-52.
[http://dx.doi.org/10.1111/j.1528-1167.2008.01492.x] [PMID:  18226171] 
[27] 
Luan G, Gao Q, Guan Y, et al. Upregulation of adenosine kinase in Rasmussen encephalitis. J Neuropathol Exp Neurol  2013; 72(11): 1000-8.
[http://dx.doi.org/10.1097/01.jnen.0000435369.39388.5c] [PMID:  24128682] 
[28] 
Luan G, Wang X, Gao Q, et al. Upregulation of neuronal adenosine a1 receptor in human rasmussen encephalitis. J Neuropathol Exp Neurol  2017; 76(8): 720-31.
[http://dx.doi.org/10.1093/jnen/nlx053] [PMID:  28789481] 
[29] 
Shirley MD, Tang H, Gallione CJ, et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med  2013; 368(21): 1971-9.
[http://dx.doi.org/10.1056/NEJMoa1213507] [PMID:  23656586] 
[30] 
Luan G, Wang X, Chen F, et al. Overexpression of adenosine kinase in patients with epilepsy associated with Sturge-Weber syndrome. Neuropsychiatry (London)  2018; 8(1): 261-8.
[http://dx.doi.org/10.4172/Neuropsychiatry.1000347] 
[31] 
Luan G, Gao Q, Zhai F, et al. Adenosine kinase expression in cortical dysplasia with balloon cells: analysis of developmental lineage of cell types. J Neuropathol Exp Neurol  2015; 74(2): 132-47.
[http://dx.doi.org/10.1097/NEN.0000000000000156] [PMID:  25575137] 
[32] 
Lamparello P, Baybis M, Pollard J, et al. Developmental lineage of cell types in cortical dysplasia with balloon cells. Brain  2007; 130(Pt 9): 2267-76.
[http://dx.doi.org/10.1093/brain/awm175] [PMID:  17711980] 
[33] 
Palmini A, Najm I, Avanzini G, et al. Terminology and classification of the cortical dysplasias. Neurology  2004; 62(6)(Suppl. 3): S2-8.
[http://dx.doi.org/10.1212/01.WNL.0000114507.30388.7E] [PMID:  15037671] 
[34] 
de Groot M, Iyer A, Zurolo E, et al. Overexpression of ADK in human astrocytic tumors and peritumoral tissue is related to tumor-associated epilepsy. Epilepsia  2012; 53(1): 58-66.
[http://dx.doi.org/10.1111/j.1528-1167.2011.03306.x] [PMID:  22092111] 
[35] 
Diamond ML, Ritter AC, Jackson EK, et al. Genetic variation in the adenosine regulatory cycle is associated with posttraumatic epilepsy development. Epilepsia  2015; 56(8): 1198-206.
[http://dx.doi.org/10.1111/epi.13044] [PMID:  26040919] 
[36] 
Boison D. Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev  2013; 65(3): 906-43.
[http://dx.doi.org/10.1124/pr.112.006361] [PMID:  23592612] 
[37] 
Li T, Lan JQ, Boison D. Uncoupling of astrogliosis from epileptogenesis in adenosine kinase (ADK) transgenic mice. Neuron Glia Biol  2008; 4(2): 91-9.
[http://dx.doi.org/10.1017/S1740925X09990135] [PMID:  19674507] 
[38] 
Li T, Quan Lan J, Fredholm BB, Simon RP, Boison D. Adenosine dysfunction in astrogliosis: cause for seizure generation? Neuron Glia Biol  2007; 3(4): 353-66.
[http://dx.doi.org/10.1017/S1740925X0800015X] [PMID:  18634566] 
[39] 
Dubé CM, Brewster AL, Richichi C, Zha Q, Baram TZ. Fever, febrile seizures and epilepsy. Trends Neurosci  2007; 30(10): 490-6.
[http://dx.doi.org/10.1016/j.tins.2007.07.006] [PMID:  17897728] 
[40] 
Pardo CA, Nabbout R, Galanopoulou AS. Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES). Neurotherapeutics  2014; 11(2): 297-310.
[http://dx.doi.org/10.1007/s13311-014-0265-2] [PMID:  24639375] 
[41] 
Kwan J. Stroke: predicting the risk of poststroke epilepsy-why and how? Nat Rev Neurol  2010; 6(10): 532-3.
[http://dx.doi.org/10.1038/nrneurol.2010.140] [PMID:  20927053] 
[42] 
Maschio M. Brain tumor-related epilepsy. Curr Neuropharmacol  2012; 10(2): 124-33.
[http://dx.doi.org/10.2174/157015912800604470] [PMID:  23204982] 
[43] 
Gebicke-Haerter PJ, Christoffel F, Timmer J, Northoff H, Berger M, Van Calker D. Both adenosine A1- and A2-receptors are required to stimulate microglial proliferation. Neurochem Int  1996; 29(1): 37-42.
[http://dx.doi.org/10.1016/0197-0186(95)00137-9] [PMID:  8808787] 
[44] 
Cunha RA. Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade. Purinergic Signal  2005; 1(2): 111-34.
[http://dx.doi.org/10.1007/s11302-005-0649-1] [PMID:  18404497] 
[45] 
Pignataro G, Maysami S, Studer FE, Wilz A, Simon RP, Boison D. Downregulation of hippocampal adenosine kinase after focal ischemia as potential endogenous neuroprotective mechanism. J Cereb Blood Flow Metab  2008; 28(1): 17-23.
[http://dx.doi.org/10.1038/sj.jcbfm.9600499] [PMID:  17457365] 
[46] 
During MJ, Spencer DD. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann Neurol  1992; 32(5): 618-24.
[http://dx.doi.org/10.1002/ana.410320504] [PMID:  1449242] 
[47] 
Williams-Karnesky RL, Sandau US, Lusardi TA, et al. Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. J Clin Invest  2013; 123(8): 3552-63.
[http://dx.doi.org/10.1172/JCI65636] [PMID:  23863710] 
[48] 
Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol  2011; 7(1): 31-40.
[http://dx.doi.org/10.1038/nrneurol.2010.178] [PMID:  21135885] 
[49] 
Li T, Steinbeck JA, Lusardi T, et al. Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain  2007; 130(Pt 5): 1276-88.
[http://dx.doi.org/10.1093/brain/awm057] [PMID:  17472985] 
[50] 
Li T, Ren G, Lusardi T, et al. Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J Clin Invest  2008; 118(2): 571-82.
[http://dx.doi.org/10.1172/JCI33737] [PMID:  18172552] 
[51] 
Burke KJ Jr, Bender KJ. Modulation of Ion Channels in the Axon: Mechanisms and Function. Front Cell Neurosci  2019; 13: 221.
[http://dx.doi.org/10.3389/fncel.2019.00221] [PMID:  31156397] 
[52] 
Boison D, Steinhäuser C. Epilepsy and astrocyte energy metabolism. Glia  2018; 66(6): 1235-43.
[http://dx.doi.org/10.1002/glia.23247] [PMID:  29044647] 
[53] 
Ugarkar BG, Castellino AJ, DaRe JM, et al. Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues. J Med Chem  2000; 43(15): 2894-905.
[http://dx.doi.org/10.1021/jm0000259] [PMID:  10956197] 
[54] 
Ugarkar BG, DaRe JM, Kopcho JJ, et al. Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues. J Med Chem  2000; 43(15): 2883-93.
[http://dx.doi.org/10.1021/jm000024g] [PMID:  10956196] 
[55] 
Erion MD, Ugarkar BG, DaRe J, et al. Design, synthesis and anticonvulsant activity of the potent adenosine kinase inhibitor GP3269. Nucleosides Nucleotides Nucleic Acids  1997; 16(7-9): 1013-21.
[http://dx.doi.org/10.1080/07328319708006124] 
[56] 
McGaraughty S, Cowart M, Jarvis MF, Berman RF. Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr Top Med Chem  2005; 5(1): 43-58.
[http://dx.doi.org/10.2174/1568026053386845] [PMID:  15638777] 
[57] 
Amtul Z. Nature’s Medicines to Treat Epileptic Seizures Studies in Natural Products Chemistry.  Elsevier 2018; pp. 129-50.
[58] 
Sandau US, Yahya M, Bigej R, Friedman JL, Saleumvong B, Boison D. Transient use of a systemic adenosine kinase inhibitor attenuates epilepsy development in mice. Epilepsia  2019; 60(4): 615-25.
[http://dx.doi.org/10.1111/epi.14674] [PMID:  30815855] 
[59] 
Albasanz JL, Perez S, Barrachina M, Ferrer I, Martín M. Up-regulation of adenosine receptors in the frontal cortex in Alzheimer’s disease. Brain Pathol  2008; 18(2): 211-9.
[http://dx.doi.org/10.1111/j.1750-3639.2007.00112.x] [PMID:  18241242] 
[60] 
Bottini N, De Luca D, Saccucci P, et al. Autism: Evidence of association with adenosine deaminase genetic polymorphism. Neurogenetics  2001; 3(2): 111-3.
[http://dx.doi.org/10.1007/s100480000104] [PMID:  11354825] 
[61] 
Rahman A. The role of adenosine in Alzheimer’s disease. Curr Neuropharmacol  2009; 7(3): 207-16.
[http://dx.doi.org/10.2174/157015909789152119] [PMID:  20190962] 
[62] 
Bekar L, Libionka W, Tian G-F, et al. Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor. Nat Med  2008; 14(1): 75-80.
[http://dx.doi.org/10.1038/nm1693] [PMID:  18157140] 
[63] 
Biaggioni I, Olafsson B, Robertson RM, Hollister AS, Robertson D. Cardiovascular and respiratory effects of adenosine in conscious man. Evidence for chemoreceptor activation. Circ Res  1987; 61(6): 779-86.
[http://dx.doi.org/10.1161/01.RES.61.6.779] [PMID:  3677336] 
[64] 
Jacobson KA. Adenosine A3 receptors: Novel ligands and paradoxical effects. Trends Pharmacol Sci  1998; 19(5): 184-91.
[http://dx.doi.org/10.1016/S0165-6147(98)01203-6] [PMID:  9652191] 
[65] 
Nilsen KE, Cock HR. Focal treatment for refractory epilepsy: Hope for the future? Brain Res Brain Res Rev  2004; 44(2-3): 141-53.
[http://dx.doi.org/10.1016/j.brainresrev.2003.11.003] [PMID:  15003390] 
[66] 
Fedele DE, Koch P, Scheurer L, et al. Engineering embryonic stem cell derived glia for adenosine delivery. Neurosci Lett  2004; 370(2-3): 160-5.
[http://dx.doi.org/10.1016/j.neulet.2004.08.031] [PMID:  15488315] 
[67] 
Boison D. Inhibitory RNA in epilepsy: Research tools and therapeutic perspectives. Epilepsia  2010; 51(9): 1659-68.
[http://dx.doi.org/10.1111/j.1528-1167.2010.02672.x] [PMID:  20633035] 
[68] 
Güttinger M, Fedele D, Koch P, et al. Suppression of kindled seizures by paracrine adenosine release from stem cell-derived brain implants. Epilepsia  2005; 46(8): 1162-9.
[http://dx.doi.org/10.1111/j.1528-1167.2005.61804.x] [PMID:  16060924] 
[69] 
Boison D. Engineered adenosine-releasing cells for epilepsy therapy: Human mesenchymal stem cells and human embryonic stem cells. Neurotherapeutics  2009; 6(2): 278-83.
[http://dx.doi.org/10.1016/j.nurt.2008.12.001] [PMID:  19332320] 
[70] 
Ren G, Boison D. Engineering human mesenchymal stem cells to release adenosine using miRNA technology RNAi and microRNA-Mediated Gene Regulation in Stem Cells.  Springer 2010; pp. 225-40.
[http://dx.doi.org/10.1007/978-1-60761-769-3_17] 
[71] 
Wilz A, Pritchard EM, Li T, Lan J-Q, Kaplan DL, Boison D. Silk polymer-based adenosine release: Therapeutic potential for epilepsy. Biomaterials  2008; 29(26): 3609-16.
[http://dx.doi.org/10.1016/j.biomaterials.2008.05.010] [PMID:  18514814] 
[72] 
Szybala C, Pritchard EM, Lusardi TA, et al. Antiepileptic effects of silk-polymer based adenosine release in kindled rats. Exp Neurol  2009; 219(1): 126-35.
[http://dx.doi.org/10.1016/j.expneurol.2009.05.018] [PMID:  19460372] 
[73] 
Pritchard EM, Szybala C, Boison D, Kaplan DL. Silk fibroin encapsulated powder reservoirs for sustained release of adenosine. J Control Release  2010; 144(2): 159-67.
[http://dx.doi.org/10.1016/j.jconrel.2010.01.035] [PMID:  20138938] 
[74] 
Horan RL, Antle K, Collette AL, et al. In vitro degradation of silk fibroin. Biomaterials  2005; 26(17): 3385-93.
[http://dx.doi.org/10.1016/j.biomaterials.2004.09.020] [PMID:  15621227] 
[75] 
Huber A, Padrun V, Déglon N, Aebischer P, Möhler H, Boison D. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci USA  2001; 98(13): 7611-6.
[http://dx.doi.org/10.1073/pnas.131102898] [PMID:  11404469] 
[76] 
Boison D, Scheurer L, Tseng JL, Aebischer P, Mohler H. Seizure suppression in kindled rats by intraventricular grafting of an adenosine releasing synthetic polymer. Exp Neurol  1999; 160(1): 164-74.
[http://dx.doi.org/10.1006/exnr.1999.7209] [PMID:  10630201] 
[77] 
Anschel DJ, Ortega EL, Kraus AC, Fisher RS. Focally injected adenosine prevents seizures in the rat. Exp Neurol  2004; 190(2): 544-7.
[http://dx.doi.org/10.1016/j.expneurol.2004.07.017] [PMID:  15530893] 
[78] 
Kobow K, Blümcke I. The methylation hypothesis: Do epigenetic chromatin modifications play a role in epileptogenesis? Epilepsia  2011; 52(Suppl. 4): 15-9.
[http://dx.doi.org/10.1111/j.1528-1167.2011.03145.x] [PMID:  21732935] 
[79] 
Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene  2002; 21(35): 5483-95.
[http://dx.doi.org/10.1038/sj.onc.1205699] [PMID:  12154409] 
[80] 
Bootsma HP, Ricker L, Hekster YA, et al. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure  2009; 18(5): 327-31.
[http://dx.doi.org/10.1016/j.seizure.2008.11.006] [PMID:  19110447] 
[81] 
Wang X, Gao Q, Zhou J, et al. The neuropsychological efficacy of vagus nerve stimulation in 56 children with catastrophic epilepsy. Neuropsychiatry (London)  2017; 7(4): 387-92.
[82] 
Shahwan A, Bailey C, Maxiner W, Harvey AS. Vagus nerve stimulation for refractory epilepsy in children: More to VNS than seizure frequency reduction. Epilepsia  2009; 50(5): 1220-8.
[http://dx.doi.org/10.1111/j.1528-1167.2008.01940.x] [PMID:  19170732] 
[83] 
Amtul Z, Aziz AA. Microbial proteins as novel industrial biotechnology hosts to treat epilepsy. Mol Neurobiol  2017; 54(10): 8211-24.
[http://dx.doi.org/10.1007/s12035-016-0279-3] [PMID:  27905012] 

Rights & Permissions Print Cite

Article Metrics

21

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1389450119666191014104347	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592

Current Drug Targets

Role of Adenosine Kinase Inhibitor in Adenosine Augmentation Therapy for Epilepsy: A Potential Novel Drug for Epilepsy

Abstract Play Pause

Related Journals

Related Books

Related Articles

Abstract